Last edition
News about "cardiovascular disease"
AstraZeneca, Ionis' Wainua Misses Phase 3 Primary Endpoint in ATTR-CM Trial
AstraZeneca and Ionis reported that Wainua (eplontersen) missed the primary endpoint in the phase 3 CARDIO-TTRansform trial for ATTR-CM, while maintaining a consistent safety profile.
Cardiovascular Disease | 10/07/2026 | By News Bureau
NOVOS Reports Positive Clinical Trial Results Showing Improvements in Vascular Aging Markers
A randomised clinical trial led by the University of Surrey found that NOVOS Core significantly improved endothelial function, arterial flexibility and systolic blood pressure in adults over 40 compared with placebo.
Cardiovascular Disease | 20/02/2026 | By News Bureau | 586
BioAge Labs Initiates Phase 1 Trial of Novel NLRP3 Inhibitor BGE-102 for Obesity Treatment
BioAge Labs, a clinical-stage biotechnology company based in Emeryville, California, has announced the initiation of a Phase 1 clinical study of BGE-102, an orally available, brain-penetrant small molecule NLRP3 inhibitor being developed for the treatment of obesity.
Cardiovascular Disease | 16/09/2025 | By Dineshwori | 262
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy